All too often the noise and attention is thrust upon the latest flashy or shiny new lures rather than on refining or redirecting the sails based upon changes in the wind patterns as more data become available.

In the book Dracula, Bram Stoker wrote:

“…the passing gleams of the moonlight between the scudding clouds crossing and passing, [are] like the gladness and sorrow of a man’s life.”

He might just as well been referring to drug company pipelines, where early stage agents rise and fall in favour as we follow their trials and tribulations from discovery and preclinical development through to evaluation in the clinic.  Success is fleeting and more often than not, many will fizzle and disappear in the blink of an eye.

Sometimes though, new information or intelligence comes together to point a different way forward.  It’s not necessarily going to be ‘better’, but like other aspects of life, taking action and moving forward is usually a sounder strategy than standing still.

Here, we look at a couple of developments that seemingly hit the skids a few years ago, but new evidence may offer some more focused direction forward…

To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by